FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.